



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/00 (2006.01)
A61P 29/00 (2006.01) A61P 37/04 (2006.01)

(21) International Application Number:

PCT/US2021/028459

(22) International Filing Date:

21 April 2021 (21.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/014,023	22 April 2020 (22.04.2020)	US
63/050,413	10 July 2020 (10.07.2020)	US
63/144,708	02 February 2021 (02.02.2021)	US

(71) Applicant: **IGM BIOSCIENCES, INC.** [US/US]; 325 East Middlefield Road, Mountain View, California 94043 (US).

(72) Inventors: **KEYT, Bruce**; IGM Biosciences, Inc., 325 East Middlefield Road, Mountain View, California 94043 (US).

METZGER, Todd; IGM Biosciences, Inc., 325 East Middlefield Road, Mountain View, California 94043 (US). **SINCLAIR, Angus**; IGM Biosciences, Inc., 325 East Middlefield Road, Mountain View, California 94043 (US).


(74) Agent: **JARECKI, Jessica L.** et al.; IGM Biosciences, Inc., 325 East Middlefield Road, Mountain View, California 94043 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: PD-1 AGONIST MULTIMERIC BINDING MOLECULES

FIG. 1



(57) Abstract: This disclosure provides multimeric binding molecules that specifically and agonistically bind to programmed cell death protein 1 (PD-1). This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating autoimmune disorders and preventing transplantation rejection.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

02 December 2021 (02.12.2021)